Clinical Trials

Phase 1 Active not recruiting

1 enrolled

Dermatologic

Melanoma, Recurrence

NCT05359445 2026-04-30

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

95 enrolled

Neoplasms, Recurrence

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Phase 1 Active not recruiting

Hodgkin Disease, Recurrence

NCT01822652 2026-04-06

GRAIN

11 enrolled

CNS

Neuroblastoma, Recurrence

NCT05047094 2026-04-06

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Phase NA Recruiting

48 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Recurrence, Skin Neoplasms

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT07501650 2026-03-30

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Phase 1 Recruiting

6 enrolled

Head and Neck Neoplasms, Recurrence

NCT05669846 2026-03-23

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase EARLY_PHASE1 Completed

37 enrolled

Neoplasms, Recurrence

NCT03445858 2026-02-18

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

22 enrolled

Lymphoma, Neoplasms, Recurrence

NCT06052839 2026-02-09

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

15 enrolled

Recurrence

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

78 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

28 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

NCT03160079 2025-11-10

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

Phase 1/2 Completed

16 enrolled 14 charts

Burkitt Lymphoma, Recurrence

NCT04220866 2025-10-29

MK-1454-002

Phase 2 Completed

18 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03383094 2025-10-07

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

126 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Phase 2 Terminated

4 enrolled 8 charts

Gynecologic

Recurrence, Endometrial Neoplasms

NCT02628574 2025-08-03

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Phase 1 Completed

109 enrolled

Neoplasm Metastasis, Recurrence

NCT03179930 2025-07-23

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

47 enrolled

Lymphoma, Recurrence

NCT04358237 2025-06-04

LUPER

Phase 1/2 Completed

28 enrolled

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

32 enrolled

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

20 enrolled

Hodgkin Disease, Recurrence

NCT06670911 2025-02-24

ACCESS-I

44 enrolled

Recurrence

NCT04815720 2025-01-08

KEYNOTE-B84

Phase 1/2 Completed

49 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Neoplasm Metastasis, Recurrence

NCT06016920 2024-12-17

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

51 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03385226 2024-12-09

PORT

46 enrolled

DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT04713514 2024-12-02

TEDOVA

180 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT03630042 2024-11-07

PembroWM

Phase 2 Completed

17 enrolled 7 charts

Waldenstrom Macroglobulinemia, Recurrence

NCT03340766 2024-10-17

HARBOUR

Phase 1 Completed

31 enrolled 29 charts